Rosalind Franklin University Helix 51 Company Saros Therapeutics Receives Second $2 Million Award to Advance Cancer Immunotherapy
NORTH CHICAGO, Ill., Oct. 2, 2026 /PRNewswire/ -- Saros Therapeutics, a company in Rosalind Franklin University of Medicine and Science's (RFU) Helix 51 biomedical incubator, has received its second National Cancer Institute (NCI) Phase II award of approximately $2 million to advance a...